Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02668653




Registration number
NCT02668653
Ethics application status
Date submitted
22/01/2016
Date registered
29/01/2016
Date last updated
6/08/2024

Titles & IDs
Public title
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Scientific title
A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)
Secondary ID [1] 0 0
2015-004856-24
Secondary ID [2] 0 0
AC220-A-U302
Universal Trial Number (UTN)
Trial acronym
QuANTUM-First
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Myeloid Leukemia 0 0
Leukemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Chemotherapy plus quizartinib - Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib

Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant

Continuation: up to 36 cycles with the experimental drug quizartinib

Active comparator: Chemotherapy plus placebo - Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo

Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant

Continuation: up to 36 cycles with placebo
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Timepoint [1] 0 0
Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment
Secondary outcome [1] 0 0
Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Timepoint [1] 0 0
Date of randomization to the date of refractory disease, relapse, or death, up to approximately 3 years after enrollment
Secondary outcome [2] 0 0
Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Timepoint [2] 0 0
Approximately Cycle 1 Day 21 (Induction) to end of Induction, up to approximately 120 days (each Induction cycle is up to 60 days)
Secondary outcome [3] 0 0
Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Timepoint [3] 0 0
Approximately Cycle 1 Day 21 (Induction) to end of Induction, up to approximately 120 days (each Induction cycle is up to 60 days)
Secondary outcome [4] 0 0
Number of Participants With Treatment-emergent Adverse Events Occurring in =10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Timepoint [4] 0 0
Date of first dose up to 30 days after last dose, up to 36 cycles following continuation (approximately 6 years 11 months, each cycle is 28 days)
Secondary outcome [5] 0 0
Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Timepoint [5] 0 0
Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)
Secondary outcome [6] 0 0
Number of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Timepoint [6] 0 0
Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)
Secondary outcome [7] 0 0
Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve at Steady State
Timepoint [7] 0 0
Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
Secondary outcome [8] 0 0
Pharmacokinetic Parameter Steady State, Maximum Plasma Concentration (Css,Max)
Timepoint [8] 0 0
Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
Secondary outcome [9] 0 0
Pharmacokinetic Parameter Time to Maximum Plasma Concentration Steady State (Tmax,ss)
Timepoint [9] 0 0
Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)

Eligibility
Key inclusion criteria
1. Must be competent and able to comprehend, sign, and date an Ethics Committee (EC) or Institutional Review Board approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests;
2. Is =18 years or the minimum legal adult age (whichever is greater) and =75 years (at Screening);
3. Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, based on the World Health Organization (WHO) 2008 classification (at Screening);
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (at the time the participant signs their first ICF);
5. Presence of FLT3-ITD activating mutation in bone marrow (allelic ratio of =3% FLT3-ITD/total FLT3);
6. Participant is receiving standard "7+3" induction chemotherapy regimen as specified in the protocol;
7. Adequate renal function defined as:

a. Creatinine clearance >50 mL/min, as calculated with the modified Cockcroft Gault equation
8. Adequate hepatic function defined as:

1. Total serum bilirubin (TBL) =1.5 × upper limit of normal (ULN) unless the participant has documented Gilbert's syndrome or the increase is related to increased unconjugated (indirect) bilirubin due to hemolysis;
2. Serum alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 × ULN;
9. Serum electrolytes within normal limits: potassium, calcium (total, or corrected for serum albumin in case of hypoalbuminemia or ionized calcium) and magnesium. If outside of normal limits, participant will be eligible when electrolytes are corrected;
10. If a woman of childbearing potential, must have a negative serum pregnancy test upon entry into this study and must be willing to use highly effective birth control upon enrollment, during the treatment period and for 6 months following the last dose of investigational drug or cytarabine, whichever is later. A woman is considered of childbearing potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months);
11. If male, must be surgically sterile or willing to use highly effective birth control upon enrollment, during the treatment period, and for 6 months following the last dose of investigational drug or cytarabine, whichever is later.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).
2. Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms;
3. Prior treatment for AML, except for the following allowances:

* Leukapheresis;
* Treatment for hyperleukocytosis with hydroxyurea;
* Cranial radiotherapy for central nervous system (CNS) leukostasis;
* Prophylactic intrathecal chemotherapy;
* Growth factor/cytokine support;
4. Prior treatment with quizartinib or other FLT3-ITD inhibitors;
5. Prior treatment with any investigational drug or device within 30 days prior to Randomization (within 2 weeks for investigational or approved immunotherapy) or currently participating in other investigational procedures;
6. History of known CNS leukemia, including cerebrospinal fluid positive for AML blasts; lumbar puncture is recommended for participants with symptoms of CNS leukemia to rule out extramedullary CNS involvement;
7. History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for at least 2 years;
8. Uncontrolled or significant cardiovascular disease, including any of the following:

* Bradycardia of less than 50 beats per minute, unless the participant has a pacemaker;
* Fridericia's Heart Rate Correction Formula (QTcF) interval >450 msec;
* Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);
* Systolic blood pressure =180 mmHg or diastolic blood pressure =110 mmHg;
* History of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);
* History of second (Mobitz II) or third degree heart block (participants with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker);
* History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening;
* History of New York Heart Association Class 3 or 4 heart failure;
* Known history of left ventricular ejection fraction (LVEF) =45% or less than the institutional lower limit of normal;
* Complete left bundle branch block;
9. Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;
10. Known active clinically relevant liver disease (eg, active hepatitis B, or active hepatitis C);
11. Known history of human immunodeficiency virus (HIV). Participants should be tested for HIV prior to Randomization if required by local regulations or EC;
12. History of hypersensitivity to any excipients in the quizartinib/placebo tablets;
13. Females who are pregnant or breastfeeding;
14. Otherwise considered inappropriate for the study by the Investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
16/06/2023
Sample size
Target
Accrual to date
Final
539
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [2] 0 0
Townsville Hospital (TTH) - Douglas
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
2298 - Waratah
Recruitment postcode(s) [2] 0 0
4814 - Douglas
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Illinois
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
New Jersey
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
West Virginia
Country [11] 0 0
Argentina
State/province [11] 0 0
Santa Fe
Country [12] 0 0
Argentina
State/province [12] 0 0
Córdoba
Country [13] 0 0
Belgium
State/province [13] 0 0
Brugge
Country [14] 0 0
Belgium
State/province [14] 0 0
Gent
Country [15] 0 0
Belgium
State/province [15] 0 0
Yvoir
Country [16] 0 0
Brazil
State/province [16] 0 0
Brasília
Country [17] 0 0
Brazil
State/province [17] 0 0
Passo Fundo
Country [18] 0 0
Brazil
State/province [18] 0 0
Porto Alegre
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Pleven
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Sofia
Country [21] 0 0
Canada
State/province [21] 0 0
Alberta
Country [22] 0 0
Canada
State/province [22] 0 0
British Columbia
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
China
State/province [24] 0 0
Beijing
Country [25] 0 0
China
State/province [25] 0 0
Fuzhou
Country [26] 0 0
China
State/province [26] 0 0
Guangzhou
Country [27] 0 0
China
State/province [27] 0 0
Lanzhou
Country [28] 0 0
China
State/province [28] 0 0
Shanghai
Country [29] 0 0
China
State/province [29] 0 0
Taiyuan
Country [30] 0 0
China
State/province [30] 0 0
Tianjin
Country [31] 0 0
China
State/province [31] 0 0
Wenzhou
Country [32] 0 0
China
State/province [32] 0 0
Xi'an
Country [33] 0 0
China
State/province [33] 0 0
Zhengzhou
Country [34] 0 0
Croatia
State/province [34] 0 0
Zagreb
Country [35] 0 0
Czechia
State/province [35] 0 0
Hradec Kralove
Country [36] 0 0
Czechia
State/province [36] 0 0
Olomouc
Country [37] 0 0
Czechia
State/province [37] 0 0
Ostrava
Country [38] 0 0
Czechia
State/province [38] 0 0
Plzen
Country [39] 0 0
Czechia
State/province [39] 0 0
Praha 2
Country [40] 0 0
France
State/province [40] 0 0
Grenoble
Country [41] 0 0
France
State/province [41] 0 0
Le Chesnay
Country [42] 0 0
France
State/province [42] 0 0
Lille
Country [43] 0 0
France
State/province [43] 0 0
Lyon
Country [44] 0 0
France
State/province [44] 0 0
Marguerittes
Country [45] 0 0
France
State/province [45] 0 0
Marseille
Country [46] 0 0
France
State/province [46] 0 0
Montpellier
Country [47] 0 0
France
State/province [47] 0 0
Paris
Country [48] 0 0
France
State/province [48] 0 0
Pessac
Country [49] 0 0
France
State/province [49] 0 0
Pierre Benite
Country [50] 0 0
France
State/province [50] 0 0
Rouen
Country [51] 0 0
France
State/province [51] 0 0
Toulouse
Country [52] 0 0
Germany
State/province [52] 0 0
Bad Saarow
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Germany
State/province [54] 0 0
Braunschweig
Country [55] 0 0
Germany
State/province [55] 0 0
Düsseldorf
Country [56] 0 0
Germany
State/province [56] 0 0
Essen
Country [57] 0 0
Germany
State/province [57] 0 0
Frankfurt am Main
Country [58] 0 0
Germany
State/province [58] 0 0
Halle
Country [59] 0 0
Germany
State/province [59] 0 0
Hamm
Country [60] 0 0
Germany
State/province [60] 0 0
Hannöver
Country [61] 0 0
Germany
State/province [61] 0 0
Heidelberg
Country [62] 0 0
Germany
State/province [62] 0 0
Leipzig
Country [63] 0 0
Germany
State/province [63] 0 0
Mutlangen
Country [64] 0 0
Germany
State/province [64] 0 0
Wuppertal
Country [65] 0 0
Hong Kong
State/province [65] 0 0
Shatin
Country [66] 0 0
Hungary
State/province [66] 0 0
Budapest
Country [67] 0 0
Hungary
State/province [67] 0 0
Debrecen
Country [68] 0 0
Hungary
State/province [68] 0 0
Pécs
Country [69] 0 0
Hungary
State/province [69] 0 0
Szombathely
Country [70] 0 0
Israel
State/province [70] 0 0
Tsifrin
Country [71] 0 0
Israel
State/province [71] 0 0
Haifa
Country [72] 0 0
Israel
State/province [72] 0 0
Jerusalem
Country [73] 0 0
Israel
State/province [73] 0 0
Peta? Tiqwa
Country [74] 0 0
Israel
State/province [74] 0 0
Ramat-Gan
Country [75] 0 0
Israel
State/province [75] 0 0
Tel Aviv
Country [76] 0 0
Italy
State/province [76] 0 0
Alessandria
Country [77] 0 0
Italy
State/province [77] 0 0
Ascoli Piceno
Country [78] 0 0
Italy
State/province [78] 0 0
Bari
Country [79] 0 0
Italy
State/province [79] 0 0
Bologna
Country [80] 0 0
Italy
State/province [80] 0 0
Genova
Country [81] 0 0
Italy
State/province [81] 0 0
Milano
Country [82] 0 0
Italy
State/province [82] 0 0
Napoli
Country [83] 0 0
Italy
State/province [83] 0 0
Novara
Country [84] 0 0
Italy
State/province [84] 0 0
Orbassano
Country [85] 0 0
Italy
State/province [85] 0 0
Palermo
Country [86] 0 0
Italy
State/province [86] 0 0
Ravenna
Country [87] 0 0
Italy
State/province [87] 0 0
Roma
Country [88] 0 0
Italy
State/province [88] 0 0
Rozzano
Country [89] 0 0
Italy
State/province [89] 0 0
Salerno
Country [90] 0 0
Italy
State/province [90] 0 0
Siena
Country [91] 0 0
Italy
State/province [91] 0 0
Torino
Country [92] 0 0
Italy
State/province [92] 0 0
Varese
Country [93] 0 0
Japan
State/province [93] 0 0
Aichi
Country [94] 0 0
Japan
State/province [94] 0 0
Ehime
Country [95] 0 0
Japan
State/province [95] 0 0
Fukui
Country [96] 0 0
Japan
State/province [96] 0 0
Fukuoka
Country [97] 0 0
Japan
State/province [97] 0 0
Gunma
Country [98] 0 0
Japan
State/province [98] 0 0
Hiroshima
Country [99] 0 0
Japan
State/province [99] 0 0
Hokkaido
Country [100] 0 0
Japan
State/province [100] 0 0
Kanagawa
Country [101] 0 0
Japan
State/province [101] 0 0
Miagi
Country [102] 0 0
Japan
State/province [102] 0 0
Nara
Country [103] 0 0
Japan
State/province [103] 0 0
Shizuoka
Country [104] 0 0
Japan
State/province [104] 0 0
Tokyo
Country [105] 0 0
Japan
State/province [105] 0 0
Akita
Country [106] 0 0
Japan
State/province [106] 0 0
Aomori
Country [107] 0 0
Japan
State/province [107] 0 0
Chiba
Country [108] 0 0
Japan
State/province [108] 0 0
Gifu
Country [109] 0 0
Japan
State/province [109] 0 0
Kagoshima
Country [110] 0 0
Japan
State/province [110] 0 0
Kobe
Country [111] 0 0
Japan
State/province [111] 0 0
Kumamoto
Country [112] 0 0
Japan
State/province [112] 0 0
Nagasaki
Country [113] 0 0
Japan
State/province [113] 0 0
Osaka
Country [114] 0 0
Korea, Republic of
State/province [114] 0 0
Busan
Country [115] 0 0
Korea, Republic of
State/province [115] 0 0
Daegu
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Hwasun
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Incheon
Country [118] 0 0
Korea, Republic of
State/province [118] 0 0
Seongnam-si
Country [119] 0 0
Korea, Republic of
State/province [119] 0 0
Seoul
Country [120] 0 0
Korea, Republic of
State/province [120] 0 0
Sowon
Country [121] 0 0
Korea, Republic of
State/province [121] 0 0
Ulsan
Country [122] 0 0
Poland
State/province [122] 0 0
Kraków
Country [123] 0 0
Poland
State/province [123] 0 0
Slupsk
Country [124] 0 0
Poland
State/province [124] 0 0
Warszawa
Country [125] 0 0
Portugal
State/province [125] 0 0
Coimbra
Country [126] 0 0
Portugal
State/province [126] 0 0
Lisboa
Country [127] 0 0
Portugal
State/province [127] 0 0
Porto
Country [128] 0 0
Romania
State/province [128] 0 0
Bucuresti
Country [129] 0 0
Romania
State/province [129] 0 0
Cluj-Napoca
Country [130] 0 0
Romania
State/province [130] 0 0
Craiova
Country [131] 0 0
Romania
State/province [131] 0 0
Târgu-Mures
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Nizhny Novgorod
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Penza
Country [134] 0 0
Russian Federation
State/province [134] 0 0
Petrozavodsk
Country [135] 0 0
Russian Federation
State/province [135] 0 0
Ryazan'
Country [136] 0 0
Russian Federation
State/province [136] 0 0
Saint Petersburg
Country [137] 0 0
Russian Federation
State/province [137] 0 0
Saratov
Country [138] 0 0
Russian Federation
State/province [138] 0 0
St. Petersburg
Country [139] 0 0
Russian Federation
State/province [139] 0 0
Tula
Country [140] 0 0
Serbia
State/province [140] 0 0
Belgrade
Country [141] 0 0
Serbia
State/province [141] 0 0
Nis
Country [142] 0 0
Serbia
State/province [142] 0 0
Novi Sad
Country [143] 0 0
Singapore
State/province [143] 0 0
Singapore
Country [144] 0 0
Spain
State/province [144] 0 0
Mallorca
Country [145] 0 0
Spain
State/province [145] 0 0
Albacete
Country [146] 0 0
Spain
State/province [146] 0 0
Alicante
Country [147] 0 0
Spain
State/province [147] 0 0
Badalona
Country [148] 0 0
Spain
State/province [148] 0 0
Barcelona
Country [149] 0 0
Spain
State/province [149] 0 0
Bilbao
Country [150] 0 0
Spain
State/province [150] 0 0
Cáceres
Country [151] 0 0
Spain
State/province [151] 0 0
Córdoba
Country [152] 0 0
Spain
State/province [152] 0 0
Girona
Country [153] 0 0
Spain
State/province [153] 0 0
Granada
Country [154] 0 0
Spain
State/province [154] 0 0
La Coruña
Country [155] 0 0
Spain
State/province [155] 0 0
Las Palmas De Gran Canaria
Country [156] 0 0
Spain
State/province [156] 0 0
Madrid
Country [157] 0 0
Spain
State/province [157] 0 0
Majadahonda
Country [158] 0 0
Spain
State/province [158] 0 0
Málaga
Country [159] 0 0
Spain
State/province [159] 0 0
Oviedo
Country [160] 0 0
Spain
State/province [160] 0 0
Pamplona
Country [161] 0 0
Spain
State/province [161] 0 0
Salamanca
Country [162] 0 0
Spain
State/province [162] 0 0
Santander
Country [163] 0 0
Spain
State/province [163] 0 0
Santiago de Compostela
Country [164] 0 0
Spain
State/province [164] 0 0
Sevilla
Country [165] 0 0
Spain
State/province [165] 0 0
Tarragona
Country [166] 0 0
Spain
State/province [166] 0 0
Valencia
Country [167] 0 0
Taiwan
State/province [167] 0 0
Niaosong District
Country [168] 0 0
Taiwan
State/province [168] 0 0
Taichung
Country [169] 0 0
Taiwan
State/province [169] 0 0
Tainan
Country [170] 0 0
Taiwan
State/province [170] 0 0
Taipei
Country [171] 0 0
Taiwan
State/province [171] 0 0
Taoyuan
Country [172] 0 0
Ukraine
State/province [172] 0 0
Cherkasy
Country [173] 0 0
Ukraine
State/province [173] 0 0
Poltava
Country [174] 0 0
Ukraine
State/province [174] 0 0
Vinnytsia
Country [175] 0 0
Ukraine
State/province [175] 0 0
Zhytomyr
Country [176] 0 0
United Kingdom
State/province [176] 0 0
Maidstone

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Daiichi Sankyo
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.

Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).

Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.
Trial website
https://clinicaltrials.gov/study/NCT02668653
Trial related presentations / publications
Cortes J, Perl AE, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Kramer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Leader
Address 0 0
Daiichi Sankyo
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02668653